Supplementary Figures – Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib

  

Supplementary Figure S1. Time-dependent ROC curves of survival at 6 months. AFP response was assessed using AFP ratio, which was calculated as follows: AFPon-treatment/AFPBaseline. 

  

Supplementary Figure S2. Waterfall plots of descriptive data. AFP ratio was calculated using the formula: AFPon-treatment/AFPBaseline. 

  

Supplementary Figure S3. Survival outcomes of patients with baseline AFP level within the normal range (< 20 ng/ml) and AFP responders. AFP response was defined as 20% reduction of serum AFP during treatment with regorafenib compared with baseline AFP.

  

Supplementary Figure S4. Survival outcomes in the Korean cohort (n = 437). Baseline AFP was classified using a cutoff value of 400 ng/mL. AFP response was defined as 20% reduction of serum AFP during treatment with regorafenib compared with baseline AFP.

  

Supplementary Figure S5. Survival outcomes in the Italian cohort (n = 141). Baseline AFP was classified using a cutoff value of 400 ng/mL. AFP response was defined as 20% reduction of serum AFP during treatment with regorafenib compared with baseline AFP.